FORM 8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                CURRENT REPORT

                    Pursuant to Section 13 or 15(d) of the 
                        Securities Exchange Act of 1934
               Date of Report (Date of earliest event reported):
                                 July 7, 1998


                       ROBERT PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
            (exact name of registrant as specified in its charter)

  NEW JERSEY                      1-1-432                         22-2429994
- --------------                  -------------                  ----------------
(State or other                 (Commission                     (IRS Employer
jurisdiction of                 File Number)                    Identification
incorporation)                                                  Number)


                              Meridian Center II
                             4 Industrial Way West
                          Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
         (Address of principal executive offices, including zip code)


     Registrant's telephone number, including area code:     732-389-1182


                              Meridian Center II
                             4 Industrial Way West
                         Eatontown, New Jersey  07724

- --------------------------------------------------------------------------------
         (Former name or former address, if changed from last report)


 
Item 5. Other Events
        ------------

        Roberts Pharmaceutical Corporation today announced that it has entered 
into an agreement with RiboGene, Inc. whereby Roberts has been contracted to 
develop and has been granted an option to market exclusively, in the U.S., 
Canada and Mexico, RiboGene's Emitasol /R/, a Phase III intranasal delivery 
formulation of metoclopramide.

        Metoclopramide in oral and injectable form is approved for use in 
treating emesis (nausea and vomiting). The intranasal dosing of Emitasol is 
protected by a U.S. use patent and is intended for both the prevention and 
treatment of chemotherapy induced emesis.

        Under the terms of this agreement, RiboGene will provide up to $7
million in funding for the development of Emitasol through completion of Phase
III trials and the submission of a New Drug Application (NDA) with the balance,
if any provided by Roberts. Roberts said that it is targeting the second half of
1999 for the submission of the NDA.

        Upon approval of the NDA, Roberts can exercise its option to market 
Emitasol under the RiboGene patents by making a milestone payment at that time 
plus subsequent royalties on product sales.

        In a separate transaction, Roberts will purchase $10 million of 
convertible preferred shares to be privately placed by RiboGene. The preferred 
shares have no voting rights and RiboGene's operating results are separate from 
Roberts' and will not be included in Roberts' income statement.

                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, 
the registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

                                              ROBERTS PHARMACEUTICAL CORPORATION
                                              ----------------------------------
                                                         (Registrant)


Date:  July 9, 1998                           By: /s/ Anthony A. Rascio
                                                 -------------------------------
                                                 Anthony A. Rascio
                                                 Vice President


 
FORWARD LOOKING STATEMENTS

        Certain statements included in Item 5 of this form 8-K are intended to 
be, and are hereby identified as, forward looking statements for purposes of the
safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as 
amended, and Section 27A of the Securities Act of 1933, as amended. The 
Registrant cautions readers that forward looking statements, including, without 
limitation, those relating to the Registrant's future business prospects, 
revenues, cost of sales, intangible dispositions and write-offs, continuing 
operations and discontinued operations, and liquidity and capital resources, are
subject to certain risks and uncertainties, including, without limitation, the 
ability of the Registrant to secure regulatory approval in the United States and
in foreign jurisdictions for the Registrant's developmental pipeline drugs, the 
efforts of the Registrant's competitors and the introduction of rival 
pharmaceutical products which may prove to be more effective than the 
Registrant's products, general market conditions, the availability of capital, 
and the uncertainty over the future direction of the healthcare industry, that 
could cause actual results to differ materially from those indicated in the 
forward looking statements.